Market Cap 175.30M
Revenue (ttm) 13.63M
Net Income (ttm) -186.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,366.54%
Debt to Equity Ratio 0.00
Volume 3,711,000
Avg Vol 2,115,850
Day's Range N/A - N/A
Shares Out 115.33M
Stochastic %K 88%
Beta 2.34
Analysts Sell
Price Target $4.45

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 875 1800
Address:
12278 Scripps Summit Drive, San Diego, United States
Joe_Mama
Joe_Mama Oct. 25 at 4:40 PM
$FATE Next we travel up the right side. It’s taken forever to drop, bottom out, and fill the base. Next we climb. Huge day tomorrow for us. GL Fate!!
0 · Reply
S_Franconi
S_Franconi Oct. 25 at 3:24 PM
$FATE Since its founding a decade ago, clinical-stage biopharmaceutical company Fate Therapeutics has pioneered approaches to cellular (re)programming of immune cells, including natural killer (NK) cells, T cells and CD34+ cells, based on the simple motto that “better cell therapies start with better cells.” These approaches have created a deep product portfolio of first-in-class cellular immunotherapies. https://www.nature.com/articles/d43747-020-00419-3#:~:text=CAR%20iPSC%2Dderived%20T%20(iT,the%2Dshelf%20iT%20cell%20immunotherapies.
1 · Reply
S_Franconi
S_Franconi Oct. 25 at 3:22 PM
$FATE Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-highlights-ft522-shelf-adr-armed-car-nk-cell#:~:text=About%20Fate%20Therapeutics'%20iPSC%20Product,and%20500%20pending%20patent%20applications.
1 · Reply
cta7978
cta7978 Oct. 25 at 12:33 AM
3 · Reply
Getthebtead
Getthebtead Oct. 24 at 8:44 PM
$FATE hoping for the best this weekend, anyone think maybe it’s already been priced in?
5 · Reply
RunnerSignals
RunnerSignals Oct. 24 at 8:36 PM
Market Warriors Flip the Script 🔥 $DFLI $FATE $PROP $ATLX $IBM started red but closed green! 💪 Bulls showed up late and turned the tide
0 · Reply
Stocksprofessional
Stocksprofessional Oct. 24 at 8:16 PM
$FATE We finally closed above 1.64 — what a solid way to wrap up the week! Momentum is clearly building, and things are starting to line up perfectly for the next leg up. Wishing all my fellow longs a fantastic weekend — you’ve earned it!
1 · Reply
radonco
radonco Oct. 24 at 7:20 PM
$FATE we focus so much on autoimmune diseases data…when will they share solid tumor her-2/neu breast cancer data?
0 · Reply
cta7978
cta7978 Oct. 24 at 7:12 PM
$FATE "However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25." Big reveal tomorrow!
1 · Reply
cta7978
cta7978 Oct. 24 at 7:04 PM
$FATE Last hour to load up.. I think full updated poster data available at ACR tomorrow morning.
0 · Reply
Latest News on FATE
Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 14, 2025, 4:01 PM EST - 9 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences


Fate Therapeutics Announces Leadership Transition

Nov 29, 2024, 1:05 PM EST - 11 months ago

Fate Therapeutics Announces Leadership Transition


Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024


Fate Therapeutics: Getting There, But Perpetually

Nov 12, 2023, 12:10 PM EST - 2 years ago

Fate Therapeutics: Getting There, But Perpetually


Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript


Fate Therapeutics: The Future Remains Cloudy

May 23, 2023, 1:40 PM EDT - 2 years ago

Fate Therapeutics: The Future Remains Cloudy


Joe_Mama
Joe_Mama Oct. 25 at 4:40 PM
$FATE Next we travel up the right side. It’s taken forever to drop, bottom out, and fill the base. Next we climb. Huge day tomorrow for us. GL Fate!!
0 · Reply
S_Franconi
S_Franconi Oct. 25 at 3:24 PM
$FATE Since its founding a decade ago, clinical-stage biopharmaceutical company Fate Therapeutics has pioneered approaches to cellular (re)programming of immune cells, including natural killer (NK) cells, T cells and CD34+ cells, based on the simple motto that “better cell therapies start with better cells.” These approaches have created a deep product portfolio of first-in-class cellular immunotherapies. https://www.nature.com/articles/d43747-020-00419-3#:~:text=CAR%20iPSC%2Dderived%20T%20(iT,the%2Dshelf%20iT%20cell%20immunotherapies.
1 · Reply
S_Franconi
S_Franconi Oct. 25 at 3:22 PM
$FATE Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-highlights-ft522-shelf-adr-armed-car-nk-cell#:~:text=About%20Fate%20Therapeutics'%20iPSC%20Product,and%20500%20pending%20patent%20applications.
1 · Reply
cta7978
cta7978 Oct. 25 at 12:33 AM
3 · Reply
Getthebtead
Getthebtead Oct. 24 at 8:44 PM
$FATE hoping for the best this weekend, anyone think maybe it’s already been priced in?
5 · Reply
RunnerSignals
RunnerSignals Oct. 24 at 8:36 PM
Market Warriors Flip the Script 🔥 $DFLI $FATE $PROP $ATLX $IBM started red but closed green! 💪 Bulls showed up late and turned the tide
0 · Reply
Stocksprofessional
Stocksprofessional Oct. 24 at 8:16 PM
$FATE We finally closed above 1.64 — what a solid way to wrap up the week! Momentum is clearly building, and things are starting to line up perfectly for the next leg up. Wishing all my fellow longs a fantastic weekend — you’ve earned it!
1 · Reply
radonco
radonco Oct. 24 at 7:20 PM
$FATE we focus so much on autoimmune diseases data…when will they share solid tumor her-2/neu breast cancer data?
0 · Reply
cta7978
cta7978 Oct. 24 at 7:12 PM
$FATE "However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25." Big reveal tomorrow!
1 · Reply
cta7978
cta7978 Oct. 24 at 7:04 PM
$FATE Last hour to load up.. I think full updated poster data available at ACR tomorrow morning.
0 · Reply
cta7978
cta7978 Oct. 24 at 6:57 PM
0 · Reply
GLPHOTOX
GLPHOTOX Oct. 24 at 5:35 PM
$FATE run baby run !
0 · Reply
Metiin
Metiin Oct. 24 at 5:22 PM
$FATE this one is warming up
0 · Reply
Stocksprofessional
Stocksprofessional Oct. 24 at 3:46 PM
$FATE 211K shares for sale at $30. My average is $1.09. I could take an amazing profit right now, but I’m here for the long haul. $30 is my target, and I have zero plans to sell a single share below that. Holding strong, riding this all the way up!
3 · Reply
Rocketman808
Rocketman808 Oct. 24 at 3:42 PM
$FATE this is my favorite type of reverse split lol
2 · Reply
lob11
lob11 Oct. 24 at 3:35 PM
$FATE Moving
0 · Reply
Rocketman808
Rocketman808 Oct. 24 at 3:35 PM
$FATE hello fellow FATErs. once again, slosh then boom! great action here due to underlying data!
1 · Reply
Jake140
Jake140 Oct. 24 at 3:30 PM
$FATE Let’s go!!!
0 · Reply
RunnerSignals
RunnerSignals Oct. 24 at 3:26 PM
$FATE started down but now flying high
0 · Reply
wenmoon_stonks
wenmoon_stonks Oct. 24 at 3:23 PM
$FATE we need a reddit run like beyonts meat. Horrible product and still ran, we have a pipeline LFG . The only thing beyonts has is some hit songs. Foh
0 · Reply
Stocksprofessional
Stocksprofessional Oct. 24 at 3:20 PM
$FATE Tick-tock! 1.64 smashing—next level 💥
1 · Reply
kshonstocks
kshonstocks Oct. 24 at 3:03 PM
$FATE on scans needs >1.65-1.66 ish to really launch
0 · Reply